Initial validation using orthotopic models: SIL204 administered subcutaneously (systemically) showed significant efficacy in ...

Grand Cayman, Cayman Islands, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage ...

Silexion Therapeutics Corp. has completed its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. SIL-204 is a next-generation siRNA candidate designed to target a broad range of ...

The research, conducted in orthotopic models where human tumor cells grow in their natural pancreatic environment, showed that subcutaneously administered SIL204 significantly reduced primary ...

Silexion Therapeutics (SLXN) announced positive data from orthotopic pancreatic cancer models demonstrating that subcutaneously administered ...

Silexion's SIL204 reduced tumor growth and metastases in pancreatic cancer models, showing strong efficacy across KRAS mutation profiles in preclinical studies.

These findings represent a significant advancement over previously reported data by providing further validation of SIL204's efficacy in the more clinically relevant orthotopic setting ...

Silexion Therapeutics' Latest Data Demonstrates that Subcutaneously Administered SIL204 Reduces Both Primary Tumors and Metastases in Clinically Relevant Orthotopic Models Where Human Pancreatic ...